Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

Phase 3Etripamil Nasal SprayPositive

AI Analysis

Summary

Milestone Pharmaceuticals has initiated the ReVeRA-301 pivotal Phase 3 trial evaluating etripamil nasal spray for self-administered treatment of atrial fibrillation with rapid ventricular rate, using the same 70 mg repeat-dose regimen that is FDA-approved for paroxysmal supraventricular tachycardia.

Clinical Trial Data

Phase

Phase 3

Importance:6/10

Sentiment:

0.60

Phase 3 trial initiationetripamilatrial fibrillationnasal sprayself-administered treatment

Related Companies

$RTSL

Read the original article

Published by GlobeNewswire Clinical Studies on August 21, 2026 12:00 PM

Read Original